GlaxoSmithKline is to invest another 200 million pounds ($330 million) on advanced manufacturing in Britain, the company said on Wednesday, underlining the draw of a tax break designed to encourage research and development.
Britain’s so-called “patent box” scheme, which offers a reduced rate of corporation tax on income derived from patents, has been hailed by GSK, its biggest drugmaker, for transforming the country as a place to invest.
{iframe}http://www.reuters.com/article/2013/12/11/glaxosmithkline-britain-idUSL6N0JP3UK20131211{/iframe}